Evidence map›Paper›PMID 26765933›Full record

ArticlePsychoneuroendocrinology2016

Hypothalamic orexin's role in exacerbated cutaneous vasodilation responses to an anxiogenic stimulus in a surgical menopause model.

Lauren M Federici, Izabela Facco Caliman, Andrei I Molosh, Stephanie D Fitz, William A Truitt, Pascal Bonaventure, Janet S Carpenter, Anantha Shekhar, Philip L Johnson

Abstract read
In one paragraph

Article in Psychoneuroendocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Lauren M FedericiDepartment of Anatomy & Cell Biology, USA; Paul and Carole Stark Neurosciences Research Institute, USA; Program in Medical Neurosciences, Paul and Carole Stark Neurosciences Research Institute, USA.
Izabela Facco CalimanDepartment of Anatomy & Cell Biology, USA; Paul and Carole Stark Neurosciences Research Institute, USA.
Andrei I MoloshPaul and Carole Stark Neurosciences Research Institute, USA; Department of Psychiatry; Indiana University School of Medicine, USA.
Stephanie D FitzDepartment of Anatomy & Cell Biology, USA.
William A TruittDepartment of Anatomy & Cell Biology, USA; Paul and Carole Stark Neurosciences Research Institute, USA.
Pascal BonaventureJanssen Research and Development LLC, USA.
Janet S CarpenterScience of Nursing Care Department, Indiana University School of Nursing, Indianapolis, IN 46202, USA.
Anantha ShekharPaul and Carole Stark Neurosciences Research Institute, USA; Department of Psychiatry; Indiana University School of Medicine, USA.
Philip L JohnsonDepartment of Anatomy & Cell Biology, USA; Paul and Carole Stark Neurosciences Research Institute, USA. Electronic address: philjohn@iupui.edu.
Neurosciences Institute · USIndiana University – Purdue University Indianapolis · USJanssen (United States) · US

Funding

Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
INDIANA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UL1): BPCAUL1RR025761 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2008 to 2011
$21.0M
NEUROBIOLOGY OF PANIC AND ANXIETY DISORDERSR01MH052619 · NIMH · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SHEKHAR, ANANTHA · 1996 to 2016
$5.0M
Indiana Clinical and Translational Science Institute-K12 ProgramKL2RR025760 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2008 to 2011
$2.2M
Hypothalamic Orexin Role in Menopause-Associated Hot Flashes and Mood/Sleep DisruK01AG044466 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI JOHNSON, PHILIP LEE · 2013 to 2016
$467k
NCATS NIH HHS UL1 TR001108NCRR NIH HHS KL2 RR025760NCRR NIH HHS RR025760NCRR NIH HHS RR025761NCRR NIH HHS UL1 RR025761NIA NIH HHS K01 AG044466NIA NIH HHS K01AG044466NIMH NIH HHS R01 MH052619
6 · The paper itself

Abstract

Distressing symptoms such as hot flashes and sleep disturbances affect over 70% of women approaching menopause for an average of 4-7 years, and recent large cohort studies have shown that anxiety and stress are strongly associated with more severe and persistent hot flashes and can induce hot flashes. Although high estrogen doses alleviate symptoms, extended use increases health risks, and current non-hormonal therapies are marginally better than placebo. The lack of effective non-hormonal treatments is largely due to the limited understanding of the mechanisms that underlie menopausal symptoms. One mechanistic pathway that has not been explored is the wake-promoting orexin neuropeptide system. Orexin is exclusively synthesized in the estrogen receptor rich perifornical hypothalamic region, and has an emerging role in anxiety and thermoregulation. In female rodents, estrogens tonically inhibit expression of orexin, and estrogen replacement normalizes severely elevated central orexin levels in postmenopausal women. Using an ovariectomy menopause model, we demonstrated that an anxiogenic compound elicited exacerbated hot flash-associated increases in tail skin temperature (TST, that is blocked with estrogen), and cellular responses in orexin neurons and efferent targets. Furthermore, systemic administration of centrally active, selective orexin 1 or 2 and dual receptor antagonists attenuated or blocked TST responses, respectively. This included the reformulated Suvorexant, which was recently FDA-approved for treating insomnia. Collectively, our data support the hypothesis that dramatic loss of estrogen tone during menopausal states leads to a hyperactive orexin system that contributes to symptoms such as anxiety, insomnia, and more severe hot flashes. Additionally, orexin receptor antagonists may represent a novel non-hormonal therapy for treating menopausal symptoms, with minimal side effects.

Indexed as

AnimalsAnti-Anxiety AgentsBody Temperature RegulationEstrogensFemaleHypothalamusMenopauseModels, AnimalNeuronsOrexin Receptor AntagonistsOrexinsOvariectomyRatsRats, Sprague-DawleyVasodilationAnti-Anxiety AgentsEstrogensOrexin Receptor AntagonistsOrexinsCutaneousEstrogenHot flashHypocretinHypothalamusMenopauseNorepinephrineOrexinSerotoninThermoregulation

Identifiers

PMID26765933
PMCPMC4752911
OpenAlexW2199059782

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.